CVRx Temettü

Temettü kriter kontrolleri 0/6

CVRx şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-7.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-7.0%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report

Nov 01

Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)

Oct 10

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Jul 31

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

Jun 18

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Feb 18

CVRx: The Path To 7x Investment Returns

Jan 07

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CVRX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CVRX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CVRx Piyasaya Karşı Temettü Getirisi

CVRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CVRX)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (CVRX) (3 yıla kadar)	n/a

Önemli Temettü: CVRX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CVRX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CVRX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CVRX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CVRx Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Price target increased by 9.8% to US$15.00

Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2024

CVRx, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)

CVRx, Inc. Announces Board Changes

President recently bought US$251k worth of stock

CVRx, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2024

Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?

Second quarter 2024 earnings: EPS misses analyst expectations

CVRx, Inc. to Report Q2, 2024 Results on Jul 29, 2024

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell Small Cap Comp Value Index

CVRx, Inc. Announces Appointment of Robert Allen John as Chief Revenue Officer, Effective June 27, 2024

Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge

New major risk - Share price stability

CVRx, Inc. Announces Executive Appointments

Consensus EPS estimates fall by 28%

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%

CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CVRx, Inc., Annual General Meeting, Jun 04, 2024

CVRx, Inc. to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Shareholder dilution

Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt

The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%

Chief Marketing & Strategy Officer notifies of intention to sell stock

CVRx, Inc. Announces Chief Executive Officer Changes, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12, 2024

CVRx, Inc. Announces Appointment of Kevin Hykes as President, Effective February 12

Full year 2023 earnings: EPS exceeds analyst expectations

CVRx, Inc. to Report Q4, 2023 Results on Jan 25, 2024

CVRx, Inc. Announces Nadim Yared Retires as Chief Executive Officer

CVRx, Inc. Announces Nadim Yare Retires as President

CVRx, Inc. Receives FDA Approval for Expanded Labing of Barostim

Price target increased by 16% to US$23.60

Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%

New minor risk - Share price stability

CVRx, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Price target decreased by 9.3% to US$19.40

CVRx, Inc. to Report Q3, 2023 Results on Oct 26, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. Revises Financial Guidance for the Full Year 2023

CVRx, Inc. to Report Q2, 2023 Results on Jul 25, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. to Report Q4, 2022 Results on Jan 26, 2023

CVRx, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2022 and Provides Revenue Guidance for the First Quarter and Full Year of 2023

CVRx, Inc. Appoints Kevin Hykes to Board of Directors

Price target increased to US$17.25

Chief Marketing & Strategy Officer notifies of intention to sell stock

Price target increased to US$14.75

CVRx, Inc. Launches New Barostim NEO2(TM) Implantable Pulse Generator

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CVRx, Inc. announced that it expects to receive $65 million in funding from Innovatus Capital Partners, LLC

CVRx, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Companies Like CVRx (NASDAQ:CVRX) Are In A Position To Invest In Growth

CVRx Pursues Revenue Growth But Operating Losses Worsen

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CVRx, Inc. Revises Earnings Guidance for the Full Year of 2022

CVRx, Inc. to Report Q2, 2022 Results on Jul 28, 2022

CVRx, Inc. Launches A New Barostim Programmer

CVRx, Inc.(NasdaqGS:CVRX) dropped from Russell 2500 Value Index

CVRx: Barostim Story Looks Well Priced In, Overvalued At Just 5x Sales

CVRx, Inc. Receives U.S. Food and Drug Administration Approval for Magnetic Resonance Conditional Labeling for Its Barostim System

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

CVRx, Inc., Annual General Meeting, Jun 07, 2022

CVRx, Inc. to Report Q1, 2022 Results on Apr 25, 2022

We Think CVRx (NASDAQ:CVRX) Can Afford To Drive Business Growth

Consensus forecasts updated

Earnings Release: Here's Why Analysts Cut Their CVRx, Inc. (NASDAQ:CVRX) Price Target To US$20.33

Full year 2021 earnings: EPS exceeds analyst expectations

CVRx, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2022

CVRx, Inc. to Report Q4, 2021 Results on Feb 15, 2022

Cvrx, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year of 2021 and First Quarter and Full Year of 2022